

Glebatumumab

Cat. No.:	HY-P99205
CAS No.:	1020264-78-1
Target:	ADC Antibody
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Glebatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glebatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glebatumumab vedotin. Glebatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity ^[1] .
In Vitro	Glebatumumab vedotin (CR011-vcMMAE) (0-2.5 µg/mL, 72 h) shows little growth inhibition in UACC62 melanoma cells without MEK inhibitor pretreatment at a concentration of 0.16 µg/mL, while the same dose of CR011-vcMMAE shows stronger growth inhibition in UACC62 cells pretreated with MEK inhibitor ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Glebatumumab vedotin (i.v., 2.5 mg/kg, 3 times in 7 days) can inhibit tumor growth and is well tolerated in CB17SC scid ^{2/?} female mice with sarcomas ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Naumovski L, et al. Glebatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. *Curr Opin Mol Ther.* 2010 Apr;12(2):248-57.
- [2]. E Anders Kolb, et al. Initial testing (stage 1) of glebatumumab vedotin (CDX-011) by the pediatric preclinical testing program. *Pediatr Blood Cancer.* 2014 Oct;61(10):1816-21.
- [3]. Xiaozhong Qian, et al. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. *Mol Oncol.* 2008 Jun;2(1):81-93.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA